Seoul

Running trials

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· Phase 3· Source

• Recruiting

  A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

  NCT07005154· Phase 2· Source

• Recruiting

  A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

  NCT07094204· Phase 1· Source

• Recruiting

  A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

  NCT06901531· Phase 3· Source

• Recruiting

  A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

  NCT06902545· Source

• Recruiting

  A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

  NCT06011954· Source

• Active, not recruiting

  A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

  NCT03816163· Phase 2· Source

• Active, not recruiting

  A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

  NCT02960022· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers2 recruiting
• Pancreatic cancer2 recruiting
• Bladder cancer1 recruiting
• Colorectal cancer1 recruiting
• Lung cancer1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

  NCT02752035· Phase 3· Source

• Completed

  A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

  NCT02677896· Phase 3· Source

• Completed

  A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

  NCT02421939· Phase 3· Source